📋 Tender Overview
Alzheimer~S Disease Diagnostics Innovation And Translation To Clinical Practice In Central Europe
Advancing Bench To Bedsidealzheimer’S Disease (Ad) Affects Millions Of Individuals Worldwide, And Currently There Are No Effective Disease-Modifying Therapies. Prompt Ad Diagnosis Is Beneficial With Respect To Care And Delay Of Disease Progression. However, The Implementation Of Modern Ad Diagnostics In Clinical Practice In Czechia And Slovakia Is Fragmented. To Address This, The Eu-Funded Addit-Ce Project Will Support The Cooperation Between Academia, Business, Government And Civil Society. The Partnership Is Expected To Strengthen Research And Innovation In The Field Of Ad Diagnostics And Introduce Novel Technologies Into Ad Clinical Management. Addit-Ce Will Help Design A National Plan For Combatting Dementia And Establish A Functional Innovation Ecosystem That Will Revolutionise Diagnostic Approaches And Continue To Serve Society Even After The Project’S Completion.
Funded Under
Widening Participation And Spreading Excellence
Total Cost
€ 4 939 299,50
Eu Contribution
€ 4 939 299,50
Coordinated By
Masarykova Univerzita
Czechia
Objective
More than 55 million people worldwide suffer from dementia. Alzheimer disease (AD) is the main cause of this fatal disorder, without any effective disease modifying therapy. Early diagnosis and lifestyle modifications can significantly reduce the costs of care and treatment. There is no conceptual plan implementing modern diagnostic methods in the clinical practice in Czechia and Slovakia. The interaction between universities and private sector developing molecular diagnostic tools is fragmented and lacking. Limited number of talented students are invested in applied AD-focused research. The aim of ADDIT-CE is to interlink two ecosystems in Brno and Bratislava region, embracing the full quadruple helix of innovation driving actors: excellent scientific teams from Masaryk University and Slovak Academy of Sciences, collaborating with top biotech companies: Geneton, BioVendor, and MultiplexDX. Societal actors will be represented by organisations such as Slovak and Czech Alzheimer Societies, Memory Center and Czech Brain Aging Study. The regional government will be involved via Ministry of Health Slovak Republic, and South Moravian Innovation Centre. The joined ecosystems will unite R&I activities focusing on new diagnostic methods and their applications and further interlink academia and business spheres by creating a pilot industrial PhD programme. ADDIT-CE will generate a joint cross-border strategy covering basic and applied research activities aiming on accelerating the development of new tools for preclinical AD diagnostics and lifestyle/pharmacological intervention monitoring. New cutting-edge technologies will be transferred into clinical practise. Results of ADDIT-CE will be used to develop the Slovak National Plan to Combat Dementia, to enrich the Czech National Plan for AD, and will be widely d
